Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease

QJM: An International Journal of Medicine

Volumn 92, Issue 1, 1999, Pages 39-45

  Foy, C J ^a   Passmore, A P ^a   Vahidassr, M D ^a   Young, I S ^a   Lawson, J T ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FREE RADICAL; LYCOPENE; RETINOL;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0032921546     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.1.39     Document Type: Article

References (38)

1. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause or consequence. Lancet 1994; 344:721-4.
2. Stadtman ER. Protein oxidation and aging. Science 1992; 257(5074):1220-4.
3. Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiat 1991; 48:1097-106.
4. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurologica Scandinavica 1989; 12(Suppl.):23-33.
5. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32:804-12.
6. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344:796-8.
7. Wayner DD, Burton GW, Ingold KU, Barclay LR, Locke SJ. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim Biophys Acta 1987; 924:408-19.
8. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12:189-98.
9. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull 1988; 24:709-11.
10. Mahoney FI, Barthel DW. Functional evaluation: Barthel Index. Maryland State Med J 1965; 14:61-5.
11. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 272:207-10.
12. American Psychiatric Association Task Force on Nomenclature and Statistics. Diagnostic and Statistic Manual of Mental Disorders, 4th edn. Washington DC, American Psychiatric Association, 1994.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44.
14. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250-60.
15. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol, Neurosurg Psychiat 1988; 51:745-52.
16. American Psychiatric Association Task Force on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn revised. Washington DC, American Psychiatric Association, 1987.
17. Thurnham DI, Smith E, Flora PS. Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem 1988; 34:377-81.
18. Vuilleumier JP, Keck E. Fluorimetric assay of vitamin C in biological materials using a centrifugal analyser with a fluorescent attachment. J Micronutrient Anal 1989; 5:25-34.
19. Whitehead TP, Thorpe GHG, Maxwell SRJ. Enhanced chemiluminescent assay for antioxidant capacity in biological fluids. Analytica Chim Acta 1992; 266:265-77.
20. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989; 35:275-82.
21. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 1992; 21:91-4.
22. Sinclair AJ, Johnstone J, Warner C, Bayer AJ. Altered plasma antioxidant status in subjects with Alzheimer's Disease and Vascular Dementia. Age Ageing 1996; 25(suppl 2):3.
23. Steinberg D, Parathasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-24.
24. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis, Arteriosclerosis 1988; 8:1-21.
25. Abella A, Messaoudi C, Laurent D, Marot D, Chalas J, Breux J, Claise C, Lindenbaum A. A method for simultaneous determination of plasma and erythrocyle antioxidant status. Evaluation of the antioxidant activity of vitamin E in healthy volunteers. Br J Clin Pharmacol 1996; 42:737-41.
26. King D, Playfer JR, Roberts NB. Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease. Postgrad Med J 1992; 68:634-7.
27. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR. Movement Disorders 1994; 9:92-7.
28. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985; 58:343-6.
29. Henderson AS, Easteal S, Jorm AF, Mackinnon AJ, Korten AE, Christensen H, Croft L, Jacomb PA. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995; 25 346:1387-90.
30. Ceballos I, Javoy-Agid F, Delacourte A, Defossez A, Lafon M, Hirsch E, Nicole A, Sinet PM, Agid Y. Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. Free Radical Res Commun 1941; 12-13:571-80.
31. Richardson JS. Free radicals in the genesis of Alzheimer's disease. Ann NY Acad Sci 1993; 695:73-6.
32. Chen L, Richardson JS, Caldwell JF, Ang LC. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 1994; 75:83-9.
33. Ceballos I, Nicole A, Briand P, Grimber G, Delacourte A, Flament S, Blouin JL, Thevenin M, Kamoun P, Sinet PME. Expression of human Cu-Zn superoxide dismutase gene in transgenic mice: model for gene dosage effect in Down syndrome. Free Radical Res Commun 1991; 12-13:581-9.
34. Ceballos-Picot I, Nicole A, Sinet PM. Cellular clones and transgenic mice overexpressing copper-zinc superoxide dismutase: models for the study of free radical metabolism and aging. EXS 1992; 62:89-98.
35. Ceballos-Picot I. Transgenic mice overexpressing copper-zinc superoxide dismutase: a model for the study of radical mechanisms and aging. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 1993; 187:308-23.
36. Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann NY Acad Sci 1994; 738: 447-54.
37. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Nat Acad Sci USA 1994; 91: 4766-70.
38. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide(1-40) in cultured hippocampal neurons. Exp Neurol 1995; 131:193-202.